Abstract:Approximately 10% of human acute leukemias are involved in chromosomal translocations between the mixed lineage leukemia ( MLL ) gene and over 50 partner genes. MLL -rearranged leukemias occur preferentially in infant and young children and are often associated with poor outcome. MicroRNAs (miRNAs) are an abundant class of small noncoding RNAs which repress gene expression and mRNA stability by base pairing with target mRNAs usually at the 3’-untranslated regions (UTRs). The ten-eleven translocation 1 ( TET1 ), the founding member of the TET family of enzymes (TET1/2/3) that convert 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), was first identified in MLL -rearranged leukemia. But its definitive role in leukemia was unclear until our recent report published in PNAS (Huang H. et al. 2013). In contrast to the frequent repression and tumor-suppressor roles of the three TET genes observed in various cancers, we showed that TET1 is a direct target of MLL-fusion proteins and significantly up-regulated in MLL -rearranged leukemia, leading to a global increase of 5hmC level. Furthermore, Tet1 plays an indispensable oncogenic role in MLL -rearranged leukemia, through coordination with MLL-fusion proteins in regulating their critical co-targets including Hoxa/Meis1/Pbx3 genes. However, whether TET1 is also post-transcriptionally regulated by miRNAs in hematopoietic cells remains unknown. In the present report, through genome-wide miRNA expression profiling assays, we found that miR-26a and miR-29a were expressed at a significantly lower level in MLL -rearranged AML than in normal controls. The down-regulation of miR-26a and miR-29a is, at least in part, attributed to the transcriptional repression mediated by MLL-fusion proteins and MYC. Interestingly, both miR-26a and miR-29a target TET1 directly at the post-transcriptional level. More importantly, we showed that miR-26a or miR-29a significantly inhibited MLL-fusion-mediated cell transformation in vitro and leukemogenesis in vivo down regulating expression of Tet1 and its downstream target genes. Thus, our data suggest that the transcriptional repression of miR-26a and miR-29a is required for the aberrant overexpression and potent oncogenic role of TET1 in MLL -rearranged leukemia, and that miR-26a and miR-29a play important tumor-suppressor role in leukemogenesis. Taken together, our data reveals a previously unappreciated signaling pathway involving the MLL-fusion/Myc ⊣ miR-26a/miR-29a ⊣ Tet1 circuit in MLL -rearranged leukemia. Our data not only provides novel insight into our understanding of the complex molecular mechanisms underlying the pathogenesis of MLL -rearranged leukemia, but also may lead to the development of novel, more effective therapeutic strategies to treat this type of dismal disease. Disclosures No relevant conflicts of interest to declare.

Reinforced identity confers cells with cancer hallmarks

A Distinct Epigenetic Signature at Targets of a Leukemia Protein

Enhancer priming by H3K4 methyltransferase MLL4 controls cell fate transition.

The Non-Cell-autonomous Function of ID1 Promotes AML Progression Via ANGPTL7 from the Microenvironment.

The potent oncogene NPM-ALK mediates malignant transformation of normal human CD4(+) T lymphocytes

Tet2 Downregulation Promotes Aml Cell Proliferation Via Pim-1 Expression

The epigenetic state of the cell of origin defines mechanisms of leukemogenesis

Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9

Single-cell multiomics reveals a gene regulatory circuit promoting leukemia cell differentiation

Integrative single-cell analysis of longitudinal t(8;21) AML reveals heterogeneous immune cell infiltration and prognostic signatures

Abstract A026: Single-cell landscape deciphering cancer Single-cell landscape deciphering cancer cell-of-origin and cellular heterogeneity in malignant transformation of 13 major tissues

An Epigenetic Perspective on Tumorigenesis: Loss of Cell Identity, Enhancer Switching, and NamiRNA Network

Leukemia confers a durable imprint on healthy hematopoietic stem and progenitor cells

Abstract 5878: ZNF397 loss triggers TET2-driven epigenetic rewiring, lineage plasticity, and AR-targeted therapy resistance

A PRC2-Kdm5b axis sustains tumorigenicity of acute myeloid leukemia

Enhancer reprogramming driven by high-order assemblies of transcription factors promotes phenotypic plasticity and breast cancer endocrine resistance

Identification of MLL-Fusion/Myc⊣miR-26a/Mir-29a⊣Tet1 Signaling Circuit in MLL-Rearranged Leukemia

Unraveling MLL1-fusion Leukemia: Epigenetic Revelations from an iPS Cell Point Mutation

A PML/RARα Direct Target Atlas Redefines Transcriptional Deregulation in Acute Promyelocytic Leukemia

TFEB links MYC signaling to epigenetic control of myeloid differentiation and acute myeloid leukemia

Cancer cell employs a microenvironmental neural signal trans -activating nucleus-mitochondria coordination to acquire stemness